Several firms, such as Exact Sciences and Foundation Medicine, saw their share values more than double during the year, while NantHealth and GenMark saw their share values shrink. 

Paced by Accelerate Diagnostics and Bio-Rad, the 360Dx Index beat the broader markets. Shares of GenMark and Opko, however, were sharply down.

Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.

Revenues at BioReference Labs fell short in the quarter but are expected to grow in the fourth quarter and next year, the company said

The prostate-specific antigen diagnostic provides blood test results in 10 minutes and can be performed in a physician's office.


The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.

The firm's revenues related to the transfer of IP dropped 58 percent year over year, while service revenues declined 3 percent, and product revenues rose 27 percent.  

Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders. 

Along with Exact, Natera and Qiagen saw sharp spikes in their stock prices, while Invitae and Opko Health each saw their share prices drop by more than 20 percent. 

The firm's net loss grew year over year and it missed the consensus Wall Street estimates on the top and bottom lines.